These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 32948465)

  • 1. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research.
    Putter JS; Seghatchian J
    Transfus Apher Sci; 2020 Oct; 59(5):102934. PubMed ID: 32948465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
    Ripoll JG; Tulledge-Scheitel SM; Stephenson AA; Ford S; Pike ML; Gorman EK; Hanson SN; Juskewitch JE; Miller AJ; Zaremba S; Ovrom EA; Razonable RR; Ganesh R; Hurt RT; Fischer EN; Derr AN; Eberle MR; Larsen JJ; Carney CM; Theel ES; Parikh SA; Kay NE; Joyner MJ; Senefeld JW
    mBio; 2024 May; 15(5):e0040024. PubMed ID: 38602414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
    Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
    Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19: Transmission, prevention, and potential therapeutic opportunities.
    Lotfi M; Hamblin MR; Rezaei N
    Clin Chim Acta; 2020 Sep; 508():254-266. PubMed ID: 32474009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.
    Yılmaz S; Ertuğrul Örüç N; Özcebe Oİ; Azap A; Çetin AT; Yenicesu İ; Öztürk A; Gündüz M; Tekin A
    Transfus Apher Sci; 2020 Oct; 59(5):102846. PubMed ID: 32593519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
    Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
    Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.
    Lung T; Kazatchkine MD; Risch L; Risch M; Nydegger UE
    Transfus Apher Sci; 2020 Oct; 59(5):102936. PubMed ID: 32919880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
    Wendel S; Fachini R; Fontão-Wendel RCL; Mello R; Velasquez CV; Machado RRG; Brito MA; Amaral M; Soares CP; Achkar R; Scuracchio P; Miyaji SC; Erdens MS; Durigon EL
    Transfusion; 2021 Dec; 61(12):3455-3467. PubMed ID: 34674284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.
    Burnouf T; Gathof B; Bloch EM; Bazin R; de Angelis V; Patidar GK; Rastvorceva RMG; Oreh A; Goel R; Rahimi-Levene N; Hindawi S; Al-Riyami AZ; So-Osman C;
    Transfus Med Rev; 2022 Jul; 36(3):125-132. PubMed ID: 35879213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [COVID-19 - BLOOD GROUPS, ANTIBODIES AND CONVALESCENT PLASMA].
    Izak M; Yahalom V; Maor Y; Zimhoni O; Cohen D; Chen J; Shinar E
    Harefuah; 2021 Mar; 160(3):139-143. PubMed ID: 33749174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.
    Kumar A; Dey AD; Behl T; Chadha S; Aggarwal V
    Int Immunopharmacol; 2021 Jan; 90():107156. PubMed ID: 33189613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.